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Abstract
Introduction: The benefits of clinical trials registration include improved transparency on clinical trials for healthcare
workers and patients, increased accountability of trialists, the potential to address publication bias and selective reporting,
and possibilities for research collaboration and prioritization. However, poor quality of information in registered records of
trials has been found to undermine these benefits in the past. Trialists’ increasing experience with trial registration and
recent developments in registration systems may have positively affected data quality. This study was conducted to
investigate whether the quality of registration has improved.
Methods: We repeated a study from 2009, using the same methods and the same research team. A random sample of 400
records of clinical trials that were registered between 01/01/2012 and 01/01/2013 was taken from the International Clinical
Trials Registry Platform (ICTRP) and assessed for the quality of information on 1) contact details, 2) interventions and 3)
primary outcomes. Results were compared to the equivalent assessments from our previous study.
Results: There was a small and not statistically significant increase from 81.0% to 85.5% in the percentage of records that
provided a name of a contact person. There was a significant increase from 68.7% to 74.9% in the number of records that
provided either an email address or a telephone number. There was a significant increase from 44.2% to 51.9% in the
number of intervention arms that were complete in registering intervention specifics. There was a significant increase from
38.2% to 57.6% in the number of primary outcomes that were specific measures with a meaningful timeframe.
Approximately half of all trials continued to be retrospectively registered.
Discussion: There have been small but significant improvements in the quality of registration since 2009. Important
problems with quality remain and continue to constitute an impediment to the meaningful utilization of registered trial
information.
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Introduction
Clinical trials registration is now broadly considered an ethical
and scientific responsibility.[1–8] In the past fifteen years, national
and regional trial registries have been established in Africa, Asia,
Australia/Oceania, Europe, North America and South Amer-
ica.[9] The WHO International Clinical Trials Registry Platform
(ICTRP) was established in 2005 with the aim of bringing
registered trial data from different trial registries together and
creating a single point of access to information on all clinical trials
conducted globally.[10] It now combines data from 15 national
and regional clinical trial registries, offering access to data from
more than 200,000 trials.
There are important advantages to the increased transparency
on clinical trial conduct and reporting brought about by these
developments. It improves access to information on clinical trials
for healthcare workers, researchers and patients [11,12]; it allows
for steps to be taken against publication bias and selective
reporting [2,12–20]; it carries the potential to increase the
accountability of those conducting clinical trial research; and it
makes the identification of gaps in the health research landscape
possible, thus facilitating priority setting in research [21–27].
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The degree to which registered trial data can be used for these
purposes depends on the completeness and meaningfulness of the
data registered. The quality of data in registered records has been
shown to be poor in the past.[2,14,15,28–41] However, clinical
trials registration has matured in recent years. Trialists may have
gotten better at registering. Moreover, registries are likely to have
improved their registration systems after the implementation of the
International Standards for Clinical Trial Registries in 2010.[42]
This study was conducted to investigate whether the poor
quality of registration observed in the past has been due to trial
registration being in its nascence, or whether it is a more persistent
problem. To do so, we repeated a study conducted by us in 2009,
using the same methods and the same research team.[2]
Methods
A random sample of 400 registered records of clinical trials that
were registered between 1 January 2012 and 1 January 2013 was
taken from the ICTRP database. Records of trials that were
registered as having an observational study design were not eligible
for the sample. For trials that were registered in more than one
registry (duplicate records), only the record with the earliest
registration date was considered eligible.[43] At the time the
sample was taken the database included trials registered in fifteen
different registries.[9]
Sample size calculation
A sample size of 380 records was chosen, to ensure that all
upper and lower 95% confidence intervals for extrapolation to the
entire ICTRP dataset, calculated using the Wilson score interval
(see further under analysis), would deviate 5% at most from the
estimated number. A sample size of 380 also fulfilled this study’s
requirements to detect relatively minor changes in the quality of
the three primary outcomes: the quality of contact details,
interventions and outcomes (minor changes were defined as a
10% increase or decrease in the proportion of adequately
registered records). It allowed for detecting an increase or decrease
of 10% (using two-tailed test and a= 0.05) with b.0.85 in the
quality of contact details and interventions and with b.0.95 in the
quality of primary outcomes.
In our previous study in 2009, 3% of trials were incorrectly
registered as interventional.[2] Therefore, a final sample size of
400 records was chosen to allow for exclusion of these trials.
Data extraction
Registry name, trial ID, target sample size, inclusion criteria for
gender and age of participants, recruitment status, date of
registration, date of first enrolment and the public and scientific
title for each record were downloaded from the ICTRP database
and imported into Excel on 13 February 2013. Records were
checked for the presence of entries in each of these fields.
All information that had to be extracted manually from the
registered records was collected between 13 February 2013 and 23
February 2013. Information was always extracted manually from
the complete registered record in the source registry.
Descriptive information on study design was extracted manu-
ally. Data on interventions and sponsorship was also extracted
manually and was then coded. The system used to code
interventions was adapted from the codes used for intervention
types on ClinicalTrials.gov.[44] Primary sponsors were coded as
being foundation, government, industry, university/hospital, or
other. Trials were coded as being industry funded (primary
sponsor was industry), partially industry funded (primary sponsor
was non-industry, but secondary sponsor or source of monetary or
material support was industry), or non-industry funded.
Records of trials that were registered as interventional but,
during manual data extraction, turned out to be records of
observational trials, diagnostic accuracy trials or treatment
protocols for continuation of treatment after inclusion in a study
protocol were excluded from further data extraction.
Descriptive statistics were generated for registry name, primary
sponsor category, intervention type, study phase, study design,
target sample size, randomization status and inclusion criteria for
gender and age of participants. Registration dates and dates of first
enrolment were compared to assess the degree of retrospective
registration.
Contact information. The presence or absence of the
following contact details was evaluated: name of a contact person
(investigator or other), email address and telephone number. The
WHO 20-item Trial Registration Data Set requires registration of
separate scientific and public contact details.[45] There was,
however, variation in registration formats for contact details
between different registries. Some registries had one field for
contact details, others had two separate fields for public and
scientific contact details and others multiple contact fields. For
records with only one contact field the presence of contact
information was extracted from that field. For records with
multiple contact fields, if the contact details were present in any of
the fields, the information was denoted to be present.
Interventions. Given the considerable variability in the types
of interventions evaluated in trials, comparison of registration
quality between different intervention categories is difficult.
Therefore, the evaluation of the quality of registered intervention
data was limited to trials that investigated drugs, biologicals or
vaccines, including active comparators. Placebo comparators were
not evaluated. For each intervention and active comparator the
presence or absence of the following five intervention specifics was
collected: name, dose, duration of the intervention, frequency of
administration and route of administration. All intervention arms
were assessed separately. Name was denoted to be present if a
company serial number or a drug name was provided. Only
interventions and active comparators mentioned in the interven-
tion field were assessed. Other texts in the record were scanned for
additional information on mentioned interventions. To assess the
overall completeness of registration of intervention specifics, a
binary outcome variable was used that could be incomplete versus
complete registration of the intervention. Complete registration
entailed the reporting of drug name, dose, duration, frequency and
route.
Outcome measures. The number of primary outcomes per
record was collected. Each primary outcome was evaluated for
specificity, using a classification system adapted from the system
used by Zarin et al in their assessment of quality of
outcomes.[30,37] If a record contained multiple outcomes, all
were assessed separately. Outcomes were classified as being a
specific measure, a domain, vague, an unexplained abbreviation,
or a part of safety monitoring.
Besides assessing the specificity of each outcome, the presence
or absence of a time frame was collected for every outcome. Some
outcomes assessed the duration of an event, the time to an event or
were safety monitoring outcomes. For these outcomes, reporting a
time frame is not possible, and the timeframe was therefore
denoted as irrelevant. Time frames were denoted to be not
meaningful when they did not specify a point in time when the
outcome was to be measured.
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Only outcomes mentioned in the outcome fields were assessed.
Other texts in the record were scanned for additional information
on mentioned outcomes.
To assess the overall quality of registration of primary outcomes,
a binary outcome variable was used that could be registration of a
specific measure with a meaningful time frame present or for
which a time frame was irrelevant, versus any other outcome.
Finally, when there was more than one intervention (or active
comparator) arm registered for a trial, or when there was more
than one primary outcome registered, all intervention (and active
comparator) arms and primary outcomes were assessed in this
study. Multiple intervention arms and primary outcomes from one
registered record are not independent. The effects of this non-
independence on our reported outcomes are expected to be
limited.
Internal inconsistency in study design
Internal inconsistencies in study design fields were identi-
fied.[46] Internal inconsistencies were defined as records with
multiple descriptors that were not compatible, such as ‘‘single-
group’’ and ‘‘controlled or randomized’’; ‘‘open-label’’ and
‘‘blinded’’; and ‘‘double-blinded’’ without subject or investigator
blinding.
Assessment rules
The assessment rules and methods for data extraction for this
study are analogous with the rules and methods used in our
previous study on the quality of registration.[2] As then, all records
were assessed for eligibility by RV who then extracted and coded
the data. A more detailed overview of the rules used in all
assessments is provided in the supporting file that accompanies our
previous publication.[2]
Analysis
95% confidence intervals (CI) were calculated for proportions of
trials in the samples using continuity corrected Wilson score
intervals with Singleton et al. adjustments for finite popula-
tions.[47–49] These 95% CIs reflect the confidence with which
these proportions, measured in our samples of records, predict true
proportions in the overall populations of all interventional trials on
the ICTRP. The quality of registration was compared between
trials registered between 17 June 2008 and 17 June 2009 [2] and
trial registered between 1 January 2012 and 1 January 2013 using
the Newcombe-Wilson test with continuity correction (with
a= 0.05).[47–49]
This study intended to analyse changes in the quality of
registration across all registries from 2008/2009 to 2012.
However, the distribution of clinical trials across the registries
changed from the former dataset to the latter, and several new
registries were added to the ICTRP database. To be able to draw
conclusions about changes in the quality of registration among the
registries that were included in our first study, we conducted a
sensitivity analysis for changes in data quality in the registered
records from the three largest registries from 2008/2009
(ClinicalTrials.gov, ISRCTN and ANZCTR).
Statistical analyses were performed using MS Excel and SPSS
20.
Figure 1. Flowcharts for the old 2009 study and for the new 2013 study.
doi:10.1371/journal.pone.0084727.g001
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Results
A sample of 400 records was taken from a total of 23,046 unique
interventional trials that were registered between 1 January 2012
and 1 January 2013. 14 records were excluded from data
extraction because the corresponding trials were of an observa-
tional or diagnostic accuracy study design or were a treatment
protocol for continuation of treatment after inclusion in a study
protocol. A total of 386 records was included for data extraction,
of which 221 (57.3% [52.2%–62.2%]) investigated drugs, biolog-
icals or vaccines (Figure 1).
Baseline data on registry name, primary sponsor category,
intervention type, study phase, study design, randomization status
and inclusion criteria for gender of participants are presented in
Table 1.
Records were additionally checked for the presence of entries in
the fields for recruitment status, date of first enrolment and the
public and scientific title. The former three were present in all
records, the latter was reported in 379 records (98.2% [96.1%–
99.2%]), which constituted a significant improvement from the
observed 95.8% in 2008/2009. Furthermore, information was
collected on sample size and age of participants. Sample size was
reported in 384 records (99.5% [97.9%–99.9%]), which was not
statistically different from the observed 98.6% in 2008/2009. The
median target sample size was 77 [IQR 39–200]. Age of
participants was reported in 375 records (97.2% [94.8%–
98.5%]), which was not statistically different from the observed
95.8% in 2008/2009. 56 records (14.5% [11.2%–18.5%])
mentioned inclusion of participants ,18 years of age. Finally,
registration dates and dates of first enrolment were compared. The
majority of records in our sample did not provide a day for the
date of first enrolment but only a month and a year, which limited
this analysis to comparing the month in which trials were
registered to the month in which the first participant was
recruited. The registration date was in a later month than the
date of first enrolment in 185 records (47.9% [42.9%–53.0%]),
which was not statistically different from the observed 53.4% in
2008/2009. This difference was more than one month in 158
records (40.9% [36.0%–46.0%]), which was not statistically
different from the observed 43.6% in 2008/2009. The median
of the difference was 8 months. Registration date and date of first
enrolment were in the same month in 76 records (19.7% [15.9%–
24.1%]). The registration date was in an earlier month than the
date of first enrolment in 125 records (32.4% [27.8%–37.3%]).
The median of this difference was 2 months.
Quality of registration of contact information
Overall, 330 records reported a name of a contact person
(85.5% [81.5%–88.8%]). 259 records provided an email address
(67.1% [62.2%–71.7%]) and 272 records a telephone number
(70.5% [65.6%–74.9%]). 289 records provided either an email
address or a telephone number (74.9% [70.2%–79.0%]). These
constituted significant improvements as compared to 2008/2009
for the presence of an email address, the presence of a telephone
number and the presence of either (Table 2). Improvement in the
presence of a name of a contact person was not significant. All
changes for the subcategories of industry, non-industry and
partially industry sponsored records were not significant. Contact
details remained present less frequently among industry sponsored
trials than among non-industry sponsored trials.
The presence of contact details was disaggregated according to
trials’ recruitment status (Table 3). The presence of names of
contact persons did not differ markedly for trials with a different
recruitment status, but email addresses, telephone numbers or
either were present more frequently among recruiting or not yet
recruiting trials than among completed trials, especially for
industry sponsored trials.
Sensitivity analysis among the three largest registries showed
effects that were congruent with the changes found in the full
dataset. From 2008/2009 (693 trials) to 2012 (260 trials), reporting
improved from 79.9% to 86.2% for the name of a contact persons,
from 57.9% to 61.9% for an email address, from 62.5% to 67.7%
for a telephone number, and from 67.2% to 70.8% for the
presence of either.
Quality of registration of interventions involving drugs,
biological or vaccines
There were 221 records of trials that investigated drugs,
biologicals or vaccines. These reported 351 experimental or active
comparator arms (Table 4). Completeness of registration of the
name of the intervention, the duration of the intervention, the
frequency of administration and the route of administration did
not significantly change between 2008/2009 and 2012. Informa-
tion on the dose was present significantly more often in 2012 than
in 2008/2009. 182 arms (51.9% [46.5%–57.1%]) were complete
in registering intervention specifics, which also constituted a
significant improvement from the observed 44.2% in 2008/2009.
Sensitivity analysis showed small improvements for the com-
pleteness of registration of all intervention characteristics in
registered records from the three largest registries. From 2008/
2009 (696 intervention arms) to 2012 (217 intervention arms),
reporting improved from 98.9% to 100.0% for the name of the
drug, from 71.3% to 82.0% for dose, from 71.0% to 79.3% for
duration, from 76.7% to 84.3% for frequency, and from 74.7% to
84.8% for route. The proportion of arms that were complete in
registering interventions specifics rose from 44.7% to 57.6%.
Quality of registration of outcome measures
The 386 included trial records reported 705 primary outcomes.
261 records (67.6% [62.7%–72.2%]) reported one primary
outcome, 62 (16.1% [12.6%–20.2%]) reported two, 29 (7.5%
[5.2%–10.7%]) reported three and 32 (8.3% [5.8%–11.6%])
reported four or more. The maximum number of primary
outcomes reported in one record was 52. Two records (0.5%
[0.1%–2.1%]) reported no primary outcome at all.
The degree of specificity of reported outcomes was assessed
(Table 5). To prevent skewing of the data, the outcomes in the
record with 52 outcomes were counted as one for this analysis (the
2nd highest number of outcomes in any record was 12). 377
primary outcomes (57.6% [53.8%–61.4%]) were specific measures
for which a meaningful time frame was present or for which a time
frame was irrelevant. This constituted a significant improvement
from the observed 38.2% in 2008/2009.
Sensitivity analysis also showed improvements for the quality of
reported primary outcomes in registered records from the three
largest registries. From 2008/2009 (1186 primary outcomes) to
2012 (401 primary outcomes), the proportion of primary outcomes
that were specific measures for which a meaningful time frame was
present or for which a time frame was irrelevant improved from
38.5% to 66.1%.
Internal inconsistencies in study design
Internal inconsistencies in the study design fields were
encountered in 10 records (2.6% [1.3%–4.9%]). This was a
significant improvement from the observed 9.3% in 2008/
2009.[46]
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Table 1. General descriptive information from the two samples of clinical trials registered in 2008/2009 and in 2012.
2008/2009 2012
Category
Number of
records Percentage of records (%)
Number of
records Percentage of records (%)
Registry name1
ClinicalTrials.gov 628 85.9 [83.2–88.3] 222 57.5 [52.4–62.5]
JPRN - - 34 8.8 [6.3–12.2]
IRCT 4 0.5 [0.2–1.5] 31 8.0 [5.6–11.3]
ANZCTR 26 3.6 [2.4–5.2] 21 5.4 [3.5–8.3]
EU-CTR - - 21 5.4 [3.5–8.3]
ISRCTN 39 5.3 [3.9–7.3] 17 4.4 [2.7–7.1]
ChiCTR 11 1.5 [0.8–2.7] 14 3.6 [2.1–6.1]
CTRI 4 0.5 [0.2–1.5] 11 2.8 [1.5–5.2]
DRKS 2 0.3 [0.0–1.1] 5 1.3 [0.5–3.2]
NTR 16 2.2 [1.3–3.6] 4 1.0 [0.3–2.8]
CRiS - - 4 1.0 [0.3–2.8]
PACTR - - 1 0.3 [0.0–1.7]
RPCEC - - 1 0.3 [0.0–1.7]
SLCTR 1 0.1 [0.0–0.9] 0 0.0 [0.0–1.2]
ReBec - - 0 0.0 [0.0–1.2]
Primary sponsor
Foundation 10 1.4 [0.7–2.6] 7 1.8 [0.8–3.9]
Government 39 5.3 [3.9–7.3] 15 3.9 [2.3–6.5]
Industry 246 33.7 [30.3–37.2] 97 25.1 [21.0–29.8]
University/hospital 398 54.4 [50.8–58.0] 245 63.5 [58.4–68.2]
Other2 37 5.1 [3.7–6.9] 19 4.9 [3.1–7.7]
Not specified 1 0.1 [0.0–0.9] 3 0.8 [0.2–2.4]
Intervention type3
Drug 385 52.7 [49.0–56.3] 197 51.0 [46.0–56.1]
Biological/vaccine 82 11.2 [9.1–13.7] 34 8.8 [6.3–12.2]
Device 49 6.7 [5.1–8.8] 31 8.0 [5.6–11.3]
Procedure/surgery 69 9.4 [7.5–11.8] 35 9.1 [6.5–12.5]
Radiation 23 3.1 [2.1–4.7] 6 1.6 [0.6–3.5]
Behavioural 76 10.4 [8.4–12.9] 39 10.1 [7.4–13.6]
Genetic4 14 1.9 [1.1–3.3] 4 1.0 [0.3–2.8]
Dietary supplements 53 7.3 [5.5–9.4] 21 5.4 [3.5–8.3]
Physical therapy 23 3.1 [2.1–4.7] 18 4.7 [2.9–7.4]
Organizational 21 2.9 [1.8–4.4] 15 3.9 [2.3–6.5]
Diagnostic 9 1.2 [0.6–2.4] 11 2.8 [1.5–5.2]
Other 16 2.2 [1.3–3.6] 11 2.8 [1.5–5.2]
Study phase5
0 10 1.4 [0.7–2.6] 4 1.0 [0.3–2.8]
I 106 14.5 [12.1–17.3] 48 12.4 [9.4–16.2]
I & II 38 5.2 [3.8–7.1] 21 5.4 [3.5–8.3]
II 122 16.7 [14.1–19.6] 57 14.8 [11.5–18.8]
II & III 16 2.2 [1.3–3.6] 9 2.3 [1.1–4.5]
III 101 13.8 [11.5–16.5] 43 11.1 [8.3–14.8]
IV 85 11.6 [9.5–14.2] 40 10.4 [7.6–13.9]
Not specified 253 34.6 [31.2–38.2] 164 42.5 [37.5–47.6]
Study design
Single arm 162 22.2 [19.3–25.3] 85 22.0 [18.1–26.5]
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Differences between registries
Differences between registries in the quality of information on
contact details, interventions and primary outcomes were assessed
(Table 6). Only registries with more than ten records, intervention
arms or outcomes, respectively, were included for this comparison.
There are differences between registries in the quality of reporting,
yet there are few that score good on all aspects of quality, or bad
on all aspects.
To learn more about how data recording formats might
influence data quality, data recording formats for contact details,
interventions and primary outcomes were denoted for each of the
registries that provided data to the WHO ICTRP at the time of
the study (Table 7).
Discussion
A persistent problem
This study was conducted using the same methods and the same
research team as our previous study on the quality of registra-
tion.[2] There have been small but significant improvements in the
quality of registration since 2009. However, important problems
with quality remain and continue to constitute an impediment to
the meaningful utilization of registered trial information.
There have been small improvements to the presence of contact
details overall. This is partially due to the larger proportion of non-
industry trials in the analysis of trials registered in 2012, which do
better on registering contact details. But across all sponsor
categories quality also improved, the main exception being the
continued lack of mentioning of names of contact persons by
industry sponsors. Explicit mentioning of the name of the principal
investigator is important to increase the accountability of trialists.
Furthermore, despite improvements, contact information such as a
telephone number or email address often remain absent.
Remarkably, trialists appear to remove contact details when trials
have been completed or stopped, in particular for industry
sponsored trials. To allow patients, healthcare workers and other
researchers to inform themselves of clinical trials, it is important
that trialists can be contacted at any stage of a trial. Such
information should remain available after a trial is completed or
stopped.
There was some improvement in the completeness of interven-
tion specifics for drug trials, however, the improvement was minor.
Contrariwise, the improvement in the quality of registered
outcomes was marked. This is a hopeful development for
systematic reviewers, since in the absence of a complete trial
protocol, registered clinical trial data constitute the only way to
identify selective reporting.[2,13,15–19] However, specific infor-
mation about the outcome in registered records is necessary to
detect selective outcome reporting as part of systematic reviews,
and still almost half of all primary outcomes do not constitute a
specific measure with a meaningful timeframe. Moreover, it has
been proposed that the specificity of outcomes should be assessed
at a greater level of granularity, to take into account more subtle
forms of selective reporting.[30]
Table 1. Cont.
2008/2009 2012
Category
Number of
records Percentage of records (%)
Number of
records Percentage of records (%)
Controlled 458 62.7 [59.1–66.1] 269 69.7 [64.8–74.2]
Crossover 79 10.8 [8.7–13.3] 31 8.0 [5.6–11.3]
Not specified 32 4.4 [3.1–6.2] 1 0.3 [0.0–1.7]
Randomization
Randomized 518 70.9 [67.4–74.1] 283 73.3 [68.6–77.6]
Non-randomized 23 3.1 [2.1–4.7] 11 2.8 [1.5–5.2]
Not specified 29 4.0 [2.7–5.7] 7 1.8 [0.8–3.9]
Not applicable 161 22.0 [19.1–25.2] 85 22.0 [18.1–26.5]
Gender
M 39 5.3 [3.9–7.3] 23 6.0 [3.9–8.9]
F 79 10.8 [8.7–13.3] 44 11.4 [8.5–15.1]
Both 599 81.9 [79.0–84.6] 308 79.8 [75.4–83.6]
Not specified 14 1.9 [1.1–3.3] 11 2.8 [1.5–5.2]
Total per category 731 100% 386 100%
1The number of registries that provide data to the ICTRP has increased from nine to fifteen in between 2008/2009 and 2012. Registry acronyms stand for:
ClinicalTrials.gov (CT.gov), Japan Primary Registries Network (JPRN), Iranian Registry of Clinical Trials (IRCT), Australian New Zealand Clinical Trials Registry (ANZCTR), EU
Clinical Trials Register (EU-CTR), International Standard Randomized Controlled Trial Number Register (ISRCTN), Chinese Clinical Trial Register (ChiCTR), Clinical Trials
Registry - India (CTRI), German Clinical Trials Register (DRKS), The Netherlands National Trial Register (NTR), Clinical Research Information Service (CRiS) Republic of
Korea, Pan African Clinical Trial Registry (PACTR), Cuban Public Registry of Clinical Trials (RPCEC), Sri Lanka Clinical Trials Registry (SLCTR) and Brazilian Clinical Trials
Registry (ReBec).
2Other sponsors consisted of persons that were registered as primary sponsor, non-governmental organizations, collaborative research institutions and clinical research
organizations.
3Overlap was possible, total in this category was greater than 731 in 2008/2009 and greater than 386 in 2012.
4Genetic interventions consisted of gene transfer therapy and somatic cell transplants.
5The presence of study phase in records was analysed separately for trials in drugs, biologicals or vaccines. 2008/2009: Of 439 trials researching these types of
interventions, study phase was reported in 370 records (84.3%). 2012: Of 221 trials researching these types of interventions, study phase was reported in 172 records
(77.8%).
doi:10.1371/journal.pone.0084727.t001
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Finally, a very large percentage of records remains registered
retrospectively, as has also been concluded by others.[50] Without
prospective registration, before enrolment of the first participant,
we cannot be certain that trial outcomes are not retrospectively
registered in such a way that favours a particular result.
In conclusion, there have been small improvements to the
quality of registered trial data, but poor quality is a persistent
problem. Recent publications have also shown concomitant results
reporting at individual registries to be problematically incomplete,
such as at ClinicalTrials.gov [51–53], despite legal obligations in
the US to report the findings of trials.[51,54]
The causes of poor quality (and learning from other
registries)
The persistent nature of poor quality of registered clinical trial
data suggests one or more pervasive causes. Although trialists
themselves have a responsibility to ensure that the information in
registered records is complete and accurate, registries can
encourage high-quality registration through quality control
processes and appropriate data recording practises.[2] Both are
addressed in the International Standards for Clinical Trial
Registries.[42]
Our analysis suggests that there are important differences
between registries with regards to registration quality. Notably,
there are few that score badly on all three aspects of quality that
we tested, or well on all. Rather, there are differences depending
on which aspect is assessed, as becomes clear from Table 6, and
from our sensitivity analyses, which showed that the three largest
registries score better on intervention and primary outcome
quality, but worse on the presence of most contact details. One
explanation for these differences is the variation in data recording
formats between registries.[31] For example, some registries
specifically ask trialists for the methods of measurement for each
outcome. Others have only free text fields for outcomes. Some
registries ask for specific details on interventions, others, again,
have only free text fields. Some registries ask trialists to categorize
interventions and outcomes, others do not. For data quality and
data aggregation purposes,[23] it is important that discrete options
are offered where there is a limited set of possible answers
(supplemented by a free text field to allow for additional
explanation where needed), that different sub-aspects of data set
Table 2. The presence of contact details in registered records in 2008/2009 and 2012.
Sponsorship Year N Name (%) Email (%) Telephone nr. (%) Email or tel. nr. (%)
Industry 2008/9 246 53.7 [47.3–59.9] 39.0 [33.0–45.4] 46.7 [40.5–53.1] 56.5 [50.1–62.7]
2012 97 53.6 [43.3–63.6] 47.4 [37.3–57.7] 57.7 [47.3–67.5] 61.9 [51.4–71.3]
Partially industry 2008/9 76 97.4 [90.1–99.5] 63.2 [51.4–73.6] 65.8 [54.1–75.9] 65.8 [54.1–75.9]
2012 25 96.0 [77.8–99.8] 72.0 [50.5–87.1] 84.0 [63.2–94.7] 84.0 [63.2–94.7]
Non-industry 2008/9 408 94.4 [91.6–96.3] 70.8 [66.2–75.1] 74.3 [69.7–78.3] 76.5 [72.1–80.4]
2012 261 96.2 [92.9–98.0] 73.6 [67.7–78.7] 73.6 [67.7–78.7] 78.5 [73.0–83.2]
Overall 2008/9 7311 81.0 [78.0–83.7] 59.4 [55.7–62.9]* 64.2 [60.6–67.6]* 68.7 [65.2–72.0]*
2012 3861 85.5 [81.5–88.8] 67.1 [62.2–71.7]* 70.5 [65.6–74.9]* 74.9 [70.2–79.0]*
Legend Table 2: Percentages of records for which different aspects of contact details were present in 2008/2009 and 2012.
* = significant difference between 2008/2009 and 2012.
1Numbers of records for subcategories do not add up to total because in 2008/2009 for one trial no primary sponsor was registered and in 2012 for three trials no
primary sponsor was registered.
doi:10.1371/journal.pone.0084727.t002
Table 3. The presence of contact details according to recruitment status for trials registered in 2012.
Sponsorship Recruitment status N Name (%) Email (%) Telephone nr. (%) Email or tel. nr. (%)
Industry Not yet recruiting 10 80.0 [44.4–96.4] 80.0 [44.4–96.4] 70.0 [35.5–91.8] 80.0 [44.4–96.4]
Recruiting 51 47.1 [33.2–61.3] 66.7 [52.0–78.8] 84.3 [70.9–92.5] 90.2 [77.9–96.3]
Completed or stopped 36 55.6 [38.4–71.6] 11.1 [3.6–26.9] 16.7 [7.0–33.4] 16.7 [7.0–33.4]
Partially industry Not yet recruiting 9 100.0 [63.1–100.0] 100.0 [63.1–100.0] 100.0 [63.1–100.0] 100.0 [63.1–100.0]
Recruiting 13 100.0 [71.8–100.0] 61.5 [32.4–84.8] 84.6 [53.8–97.3] 84.6 [53.8–97.3]
Completed or stopped 3 66.7 [12.7–98.2] 33.3 [1.8–87.3] 33.3 [1.8–87.3] 33.3 [1.8–87.3]
Non-industry Not yet recruiting 51 100.0 [91.3–100.0] 88.2 [75.5–95.1] 94.1 [82.8–98.5] 96.1 [85.5–99.3]
Recruiting 144 95.1 [89.9–97.8] 79.2 [71.5–85.3] 79.2 [71.5–85.3] 85.4 [78.4–90.5]
Completed or stopped 66 95.5 [86.5–98.8] 50.0 [37.6–62.4] 45.5 [33.4–58.1] 50.0 [37.6–62.4]
Overall Not yet recruiting 701 97.1 [89.2–99.5] 88.6 [78.2–94.6] 91.4 [81.7–96.5] 94.3 [85.3–98.1]
Recruiting 2081 83.7 [77.8–88.2] 75.0 [68.5–80.6] 80.8 [74.6–85.7] 86.5 [81.0–90.7]
Completed or stopped 1051 81.0 [71.9–87.7] 36.2 [27.2–46.2] 35.2 [26.4–45.2] 38.1 [29.0–48.1]
Legend Table 3: Percentages of records for which different aspects of contact details were present for recruiting and not-recruiting trials.
1Numbers of records for subcategories do not add up to 386 because for three trials no primary sponsor was registered.
doi:10.1371/journal.pone.0084727.t003
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items are specifically queried (Table 7), and that the data recording
formats are harmonized across all individual registries. A second
explanation for the differences in the quality of registration
between registries is the level of quality control that registries
apply.
The differences in the quality of registration of different data
items found in this study suggest that registries can learn from each
other. Differences between registries in terms of data recording
formats and their consequences for data quality deserve to be
studied in more detail, so that registries can improve their formats
based on the lessons from other registries. Registries could also
draw lessons from each other about quality control, for example
with regards to the information that is considered mandatory and
a precondition for registration, and the different tiers of data
checking (e.g. automated checks and manual checks [30,42]) that
can be implemented to detect incomplete or non-meaningful
entries. The International Standards for Clinical Trial Registries
state that benchmarking of registries should be one of the next
steps in standards development for registries.[42]
Enforcement
To be able to make use of the potential benefits that clinical
trials registration offers, it is of paramount importance that
registration is complete and accurate. However, it must also be
comprehensive.[2] Enforcement of clinical trials registration has
increased substantially over the past decade,[55] owing to national
legislation on registration [4,30,56], policies by journal editors and
publishers making registration a prerequisite for publication [1,5–
7,57], ethics committees and national research ethics oversight
agencies requiring registration as part of procedures for ethics
approval [3,55,58], policies by funders making registration a
prerequisite for grant approval [59], international codes of
research practice that recommend trial registration, such as the
SPIRIT 2013 and CONSORT 2010 statements which include
sections recommending the admission of trial registration details to
both clinical trial protocols and reports [60,61], international
codes of research ethics, such as the declaration of Helsinki [62],
and self-regulation by universities [55] and the pharmaceutical
industry [8]. Despite these measures, a proportion of trials
currently remains unregistered, especially in countries lacking
legislation on trial registration.[63–67]
National legislation is crucial in enforcing the registration of all
clinical trials.[4] Several of the other enforcement measures
outlined above have been instrumental in creating momentum for
clinical trials registration, such as journal and ethics review board
requirements for registration, yet not all journal editors require
registration as a pre-condition for publication,[67] not all clinical
trials are conducted with the goal of publication,[4] and not all
ethics committees have policies on clinical trials registration in
place [58]. Therefore, it is imperative that all countries that have
not implemented legislation on trial registration do so.[4]
Furthermore, it is important that the remit of legislation on
registration should cover all possible clinical trials, as is being
recognized in the US and the EU.[68,69] Currently, in those
Table 4. The completeness of intervention specifics in registered records in 2008/2009 and 2012.
Year N Name (%) Dose (%) Duration (%) Frequency (%) Route (%) All complete (%)
2008/9 726 98.2 [96.9–99.0] 70.5 [67.1–73.8]* 70.0 [66.5–73.2] 75.8 [72.5–78.8] 73.7 [70.3–76.8] 44.2 [40.6–47.9]*
2012 351 96.6 [94.0–98.1] 77.5 [72.7–81.7]* 68.9 [63.8–73.7] 73.2 [68.2–77.7] 79.2 [74.5–83.2] 51.9 [46.5–57.1]*
Legend Table 4: Percentages of total number of intervention (and active comparator) arms for which different intervention specifics were present in 2008/2009 and
2012.
* = significant difference between 2008/2009 and 2012.
doi:10.1371/journal.pone.0084727.t004
Table 5. Degree of specificity of primary outcomes in 2008/2009 and 2012.
Classification 2008/9 (N=1271) 2012 (N=654) Examples
Specific measure (%) 47.1 [44.4–49.9]* 69.1 [65.4–72.6]* All-cause mortality, quality of life by SF-36, pulmonary
functioning by FEV-1
Domain (%) 36.7 [34.1–39.4]* 21.1 [18.1–24.5]* Freedom from progression, quality of life, pulmonary
functioning
Vague (%) 5.4 [4.3–6.8]* 3.2 [2.1–4.9]* Efficacy, symptoms, laboratory parameters
Unexplained abbreviation (%) 3.5 [2.6–4.6]* 1.2 [0.6–2.5]* Any unexplained abbreviation
Safety monitoring (%) 7.3 [6.0–8.9] 5.4 [3.8–7.4] Adverse event monitoring, drug toxicities, complications
Time
Time present (%) 65.9 [63.3–68.5] 63.3 [59.5–67.0] Mortality at one year
Time present, not meaningful (%) 10.8 [9.2–12.6]* 7.6 [5.8–10.0]* ECG twice a year, social impact throughout study
Time absent (%) 7.7 [6.3–9.3]* 13.8 [11.3–16.7]*
Time irrelevant (%) 15.6 [13.7–17.7] 15.3 [12.7–18.3] Duration of stay in ICU, time to progression
Legend Table 5: The specificity and presence of a time frame for primary outcomes, presented as percentages of the total number of primary outcomes in 2008/2009
and 2012.
* = significant difference between 2008/2009 and 2012.
doi:10.1371/journal.pone.0084727.t005
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countries where legislation to enforce registration is present, its
remit is often limited to a sub-set of trials.[30,68]
With regards to enforcement, the commitment of the pharma-
ceutical industry to clinical trials registration is important and the
past development of a Joint Position of several pharmaceutical
associations on the disclosure of clinical trial information via
clinical trial registries and databases is laudable.[8] However, the
Joint Position needs revisiting on three important aspects. First,
currently, it allows for registration after commencement of patient
enrolment. This is in contradiction with policies on clinical trial
registration by WHO and the International Committee of Medical
Journal Editors (ICMJE).[1,2] Second, it allows trialists to
withhold data specified by the WHO Minimum Trial Registration
Data Set if they consider it sensitive. This, too, is in contradiction
with policies on clinical trial registration by WHO and the
ICMJE.[1,2] Third, the Joint Position mentions that ‘‘registration
of clinical trials on any one of a number of free, publicly accessible,
internet-based registries should achieve the intended objectives’’.
To ensure the quality of registered trial data, the WHO ICTRP
search portal only provides access to data from trials registered at
registries that meet certain quality standards (excluding, for
example, registries managed by for-profit agencies).[70] To realize
a single point of access to all clinical trial data conducted globally,
it is important that the pharmaceutical associations include a
commitment to registration in WHO approved registries in the
next update of their Joint Position, as the ICMJE already has.[7]
Finally, enforcement of trial registration by the pharmaceutical
industry would be further advanced if support for clinical trials
registration and results reporting would not be limited to
statements from the pharmaceutical associations, but if more
individual pharmaceutical companies would subscribe to the
AllTrials campaign, following the example of GlaxoSmith-
Kline.[71]
Besides increasing the number of trials that is registered,
enforcing measures could also help improve the quality of
registration. Journal editors, for example, have been called upon
to not only enforce registration itself, but to also implement quality
control procedures.[19] Although editors have made clear that
trial registration with missing or uninformative fields for the
minimum data elements is inadequate,[1,5,57,72] little is known
about to what degree journals are putting such measures into
practice.[6] Similarly, both in the EU and in the US legislature
supports the WHO Minimum Trial Registration Data Set – the
minimum amount of trial information that must appear in a
register in order for a given trial to be considered fully
registered.[73,74] Failure to comply with registration legislation
may result in penalties or withholding of federal grants.[54] Yet,
little is known to what extent legislators are planning to invoke
such measures, and whether the quality of registration could play a
role in such decisions. For both legislators and journal editors
discussion needs to be initiated on how far measures should go to
discourage incomplete or inadequate registration. This applies to
both the initial registration of a clinical trial, which was the subject
of this study, as for results reporting in registry databases.[51–53]
Conclusion
There have been small but significant improvements in the
quality of registration since 2009. However, important problems
with quality remain and continue to constitute an impediment to
the meaningful utilization of registered trial information. More
effort needs to be made to improve data recording formats,
enhance quality control measures and scale up enforcement of trial
registration.
Table 6. The quality of information on contact details, interventions and primary outcomes per registry for trials registered in
2012.
Contact details Intervention Primary outcomes
Name present (%)
Email or tel.nr. present
(%) All intervention specifics complete (%)
Outcome was a specific
measure with a meaningful
or irrelevant timeframe (%)
Registry name1
ClinicalTrials.gov 83.8 [78.1–88.2] 68.9 [62.4–74.8] 54.0 [46.9–61.1] 68.6 [63.4–73.4]
JPRN 91.2 [75.3–97.7] 58.8 [40.9–74.8] 17.6 [7.4–35.1] 13.8 [6.6–25.9]
IRCT 100.0 [86.4–100.0] 100.0 [86.4–100.0] 65.6 [46.9–80.8] 76.7 [65.2–85.4]
ANZCTR 100.0 [80.9–100.0] 100.0 [80.9–100.0] 100.0 [73.4–100.0] 76.9 [56.0–90.2]
EU-CTR 19.0 [6.3–42.5] 85.7 [62.8–96.2] 14.3 [4.7–33.5] 69.0 [49.1–84.0]
ISRCTN 100.0 [77.2–100.0] 58.8 [33.6–80.5] – 1 25.0 [11.5–45.1]
ChiCTR 100.0 [73.4–100.0] 100.0 [73.4–100.0] 0.0 [0.0–34.2] 0.0 [0.0–14.0]
CTRI 100.0 [68.1–100.0] 100.0 [68.1–100.0] 95.0 [73.2–99.7] 25.0 [12.8–42.5]
DRKS - 1 - 1 - 1 - 1
NTR - 1 - 1 - 1 - 1
CRiS - 1 - 1 - 1 - 1
PACTR - 1 - 1 - 1 - 1
RPCEC - 1 - 1 - 1 - 1
Legend Table 6:
1Less than 10 records, arms or outcomes, respectively.
doi:10.1371/journal.pone.0084727.t006
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